NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional) | RFA RM 22 018

Opportunity Information: Apply for RFA RM 22 018

The NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional), announced by the National Institutes of Health under funding opportunity number RFA-RM-22-018 (CFDA 93.310), is a competitive grant program designed to back individual scientists who show exceptional creativity and who are willing to pursue research ideas that are unusually bold. The central purpose is to support highly innovative, potentially transformative work that could meaningfully advance human health. This program sits within NIH's broader High-Risk, High-Reward Research effort funded through the NIH Common Fund, which is aimed at enabling projects that may be too unconventional or early-stage to fit neatly into standard funding mechanisms.

A defining feature of this opportunity is its emphasis on "pioneering" research, meaning the proposed project should represent a substantially different scientific direction compared with what the applicant is already doing, and it should stand apart from directions already being widely pursued by others. NIH is explicitly looking for new trajectories, not incremental extensions of an existing research portfolio. At the same time, the program is deliberately broad in scientific scope: proposals can come from across NIH's mission areas, including behavioral, social, biomedical, applied, and formal sciences, and may span basic, translational, or clinical research. As indicated by "Clinical Trial Optional," applications may include a clinical trial when appropriate, but a clinical trial is not required.

The announcement also places a strong, explicit priority on reaching the best researchers by encouraging applications that reflect the full diversity of the research workforce. Individuals from diverse backgrounds, and from the full spectrum of eligible institutions across all geographic locations, are strongly encouraged to apply. Eligibility is broad and includes many types of U.S.-based organizations and government entities, such as state, county, city, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized governments); public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (outside of higher education); for-profit organizations (other than small businesses); and small businesses. The opportunity also highlights additional categories of applicants that are especially encouraged or recognized, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), faith-based or community-based organizations, eligible federal agencies, regional organizations, Indian/Native American tribal governments other than federally recognized, and U.S. territories or possessions.

Foreign eligibility is restricted in specific ways. Non-domestic (non-U.S.) entities or foreign institutions are not eligible to apply directly, and non-domestic components of U.S. organizations are not eligible to apply. However, foreign components, as defined under the NIH Grants Policy Statement, are permitted, which generally means a U.S. applicant organization may include certain allowable international elements of the project when justified and consistent with NIH policy.

From the funding details provided, this is a discretionary grant mechanism, with an award ceiling listed as 700,000. The original closing date for the opportunity was 2022-09-09, and the posting indicates it was created on 2022-04-13. Overall, the program is best understood as a prestigious NIH pathway for individual investigators who can articulate a compelling, high-risk idea with the potential for outsized impact, especially when that idea breaks meaningfully from established lines of work and could open up new scientific ground relevant to improving human health.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310.
• This funding opportunity was created on 2022-04-13.
• Applicants must submit their applications by 2022-09-09. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $700,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA RM 22 018

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: